ArticleScientific reports2019
Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Treating Initial and RecurrentMicroorganisms · 2026Article
- Trends and Disparities inGastroenterology research and practice · 2026Article
- Factors associated with failure of fecal microbiota transplant for recurrentTherapeutic advances in gastroenterology · 2025Article
- The sympathetic nervous system drives hyperinflammatory responses to Clostridioides difficile infection.Cell reports. Medicine · 2024Article
- ImprovingAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives.Gut pathogens · 2023Review
- A Predictive Model to Identify ComplicatedOpen forum infectious diseases · 2023Article
- Analysis of infections among patients with historical culture positive for extended-spectrum beta-lactamase (ESBL)-producingAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Diversity, Dynamics and Therapeutic Application ofViruses · 2022Review
- Trends and Disparities in Outcomes ofJournal of clinical medicine research · 2022Article
- Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism.Nature communications · 2022Article
- Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to TargetPharmaceuticals (Basel, Switzerland) · 2022Article
- Fecal Microbiota Transplant in Severe and Non-SevereJournal of clinical medicine · 2021Article
- Defining the black box: a narrative review of factors associated with adverse outcomes from severeTherapeutic advances in gastroenterology · 2021Review
- Article
- Assessment of Kidney Injury as a Severity Criteria forOpen forum infectious diseases · 2020Article
- Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship.Advances in therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe Clostridioides difficile infection (CDI) is associated with poorer outcomes. We aimed to identify risk factors and treatment outcomes of severe CDI. This was a retrospective cohort study. Eligible patients from January to December 2012 were recruited. Severity definitions were in accordance with SHEA/IDSA 2010 guideline. Treatment outcomes were (1) diarrhoea persistence, (2) CDI recurrence, (3) major complications despite treatment and (4) 30-day mortality. Two hundred and seventy-two patients were included and 40% had severe CDI. High APACHE II score (aOR 1.112, 95% CI 1.014-1.219; p < 0.05), high C-reactive protein (aOR 1.011; 95% CI 1.004-1.019; p < 0.01) and carbapenem usage in past 90 days (aOR 3.259; 95% CI 1.105-9.609; p < 0.05) were independent risk factors of severe CDI. Majority received oral metronidazole as sole treatment (92.6% for mild-moderate, 83.9% for severe, 77% for severe-complicated). Diarrhoea persistence was 32% versus 50% (p < 0.01), CDI recurrence 16.6% versus 16.5% (p > 0.05), major complications 1.2% versus 11% (p < 0.001) and 30-day mortality 7.4% versus 20.2% (p < 0.01) in mild-moderate CDI and severe CDI groups respectively. Oral metronidazole for severe CDI was associated with persistent diarrhoea, major complications and mortality. Risk factors for severe CDI can guide doctors in diagnosing severe CDI earlier and instituting oral vancomycin treatment to improve outcomes from severe CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.